GlaxoSmithKline : Getting ahead of HIV presentation

Meet GSK Management

Getting ahead of HIV

29 November 2021

Conference call and webcast for analysts and institutional investors

Cautionary statement regarding forward-looking statements

This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward- looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D 'Risk factors' in the Group's Annual Report on Form 20-F for FY 2020 and any impacts of the COVID-19 pandemic. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

All outlooks, targets, ambitions and expectations regarding future performance should be read together with the section "Basis of preparation, assumptions and cautionary statement on pages 5-7 of our stock exchange announcement relating to an update to investors dated 23 June 2021 and with the section "Outlook, assumptions and cautionary statements" on pages 60 and 61 of our third quarter 2021 earnings release.

2

Agenda

ViiV Healthcare: a focused, competitive HIV company, backed by the scale of GSK

Reshaping and delivering HIV treatment and prevention

Leaders and disruptors in innovation - the future is long-acting

Q&A

David Redfern,

Chief Strategy Officer, GSK

Chairman, ViiV Healthcare

Deborah Waterhouse,

CEO, ViiV Healthcare

Dr Kimberly Smith,

Head of R&D, ViiV Healthcare

David Redfern,

Deborah Waterhouse,

Dr Kimberly Smith

3

Global specialist HIV company, focused on ending HIV/AIDS

How we meet the challenge

Our mission is to
leave no person	Leaders and
living with HIV
disruptors in
behind.	innovation

2009		2012		2013

GSK and Pfizer1	Shionogi2 became	First dolutegravir
created a joint	partner and	launch in the US
venture dedicated to	shareholder
HIV

Focused and	Built on novel	Strong commitment
agile, backed by	collaborations and	to communities
scale of GSK	powerful partnerships

2016		2019		2020		2021

Acquired BMS3 HIV	Launched Dovato	Launched Rukobia,	Launched Cabenuva, first
pipeline and		first attachment	long-acting (LA) injectable
discovery assets		inhibitor	Strengthened pipeline with
			Halozyme4 and Shionogi
			collaborations

1. Pfizer Inc. 2. Shionogi & Company 3. Bristol-Myers Squib Company 4. Halozyme, Inc.

4

Reshaping and delivering HIV treatment and prevention

Ale,

Living with HIV,

Uruguay

5